Master Class
Christoph Correll, MD
Professor of Psychiatry, Chair Child and Adolescent Psychiatry
(1) The Zucker Hillside Hospital; (2) Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; (3) The Feinstein Institutes for Medical Research; (4) Charité - Universitätsmedizin Berlin
Zucker School of Medicine at Hofstra/Northwell, New York, USA
Brooke Kempf, MSN, PMHNP-BC
Hospitalist, Hamilton Center CMHC, Terre Haute, IN; Adjunct Faculty, Indiana University of Indianapolis, Indianapolis, IN
Hamilton Center CMHC
Indiana University of Indianapolis
Many patients with bipolar disorder struggle to adhere to prescribed treatments because of their complex daily regimens, adverse effects (AEs), and various patient-specific factors. Fortunately, several antipsychotics for BD-I have long-acting injectable (LAI) formulations, which have been shown to improve treatment adherence beyond that of standard oral formulations. Participate in this session to gain a comprehensive understanding of the safety, efficacy, and pharmacokinetics of the currently available long-acting injectable (LAI) antipsychotics for BD-I. Learn from expert faculty how to evaluate the distinctive characteristics of patients with BD-I who might benefit from LAI treatment. By integrating patient-centered care strategies, including motivational interviewing, attendees will acquire the tools to foster collaborative communication and enhance treatment acceptance among patients with BD-I.
This session is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.